The conference call can be accessed by dialing 88 within the U.S. Quest Diagnostics will hold its quarterly conference call to discuss financial results beginning at 8:30 a.m. The additional tables attached below include reconciliations of non-GAAP adjusted measures to GAAP measures. We believe that these non-GAAP measures are useful to investors and analysts to evaluate our performance period over period and relative to competitors, as well as to analyze the underlying trends in our business and to assess our performance. Management may use these non-GAAP measures to evaluate our performance period over period and relative to competitors, to analyze the underlying trends in our business, to establish operational budgets and forecasts and for incentive compensation purposes. Non-GAAP adjusted measures should not be considered as an alternative to the corresponding measures determined under GAAP. Non-GAAP adjusted measures are presented because management believes those measures are useful adjuncts to GAAP results. The term "adjusted" refers to non-GAAP operating performance measures that exclude special items such as restructuring and integration charges, certain financial impacts resulting from the COVID-19 pandemic, amortization expense, excess tax benefits ("ETB") associated with stock-based compensation, costs associated with donations, contributions, and other financial support through Quest for Health Equity (our initiative with the Quest Diagnostics Foundation to reduce health disparities in underserved communities), gains and losses associated with changes in the carrying value of our strategic investments, a gain on sale of an ownership interest in a joint venture, and other items. Net income attributable to Quest DiagnosticsĪs used in this press release the term "reported" refers to measures under accounting principles generally accepted in the United States ("GAAP").
Operating income as a percentage of net revenues Net income attributable to Quest Diagnostics (b) Operating income as a percentage of net revenues (b)
(dollars in millions, except per share data)
#CALL QUEST DIAGNOSTICS FOR RESULTS FULL#
2, 2023 / PRNewswire/ - Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today financial results for the fourth quarter and full year ended December 31, 2022.
Fourth quarter COVID-19 testing revenues of $184 million, down 74.6% from 2021.Fourth quarter base business revenues of $2.15 billion, up 6.3% from 2021.Fourth quarter reported diluted earnings per share ("EPS") of $0.87, down 72.1% from 2021 and adjusted diluted EPS of $1.98, down 40.5% from 2021.Fourth quarter revenues of $2.33 billion, down 15.0% from 2021.
0 kommentar(er)
